<DOC>
	<DOCNO>NCT00838214</DOCNO>
	<brief_summary>This multicentre , multinational clinical study . It comprise two consecutive segment ( A B ) . Segment A design randomize , double-blind , double-dummy , active-controlled , two-arm parallel-group study . The patient receive either budesonide prednisone 6 month . During segment B patient receive budesonide open treatment additional 6 month . In confirmatory study proportion patient complete response compare two treatment group . Complete response define biochemical remission ( =serum level ASAT ALAT within normal range ) individual last visit segment A lack steroid specific side effect throughout segment A .</brief_summary>
	<brief_title>Budesonide 3x3mg/d Versus Prednisone Active Autoimmune Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>age 10 70 year Diagnosis acute AIH accord Alvarez score normal range TPMT activity normal ACTH test negative pregnancy test screening female childbearing potential write informed consent presence Hepatitis A , B , C , E G virus infection liver cirrhosis clinical sign portal hypertension PBC PSC history hypersensitivity study medication</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>